nct_id,id,DRUGID,DRUGNAME,DRUGTYPE,DISEASES,DRUGSTAT,Target Name,PCHEMCID,HIGHSTAT,HIGHDISE
NCT04730323,12911794,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04583592,12912343,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04583592,12912343,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04583592,12912343,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04345601,12912810,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04715763,12927779,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04681430,12927962,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04681430,12927962,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04681430,12927962,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04623021,12928300,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04623021,12928300,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04623021,12928300,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04604704,12928416,DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04474457,12929102,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04469114,12929118,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04452097,12929201,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04411433,12929369,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04411433,12929370,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04411433,12929371,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04411433,12929373,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04363827,13003601,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04362813,13003602,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04357808,13003618,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04336332,13003663,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04331600,13003676,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04331600,13003676,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04331600,13003676,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04649021,13018264,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04640168,13018292,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04640168,13018295,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04640168,13018295,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04640168,13018295,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04593940,13018524,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04593940,13018524,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04593940,13018524,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04591210,13018540,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04591210,13018541,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04546581,13018747,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04546581,13018747,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04546581,13018747,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04530617,13018840,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04530617,13018840,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04530617,13018840,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04501978,13018963,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04501978,13018963,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04501978,13018963,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04357366,13019514,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04322396,13019606,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04322396,13019607,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04312009,13019633,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04311177,13019637,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04655586,13025443,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04649151,13025455,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04529525,13025891,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04470427,13026073,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04419025,13026239,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04373733,13026367,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04363502,13026386,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04338828,13026439,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04335201,13026451,DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04331834,13026456,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04328012,13026465,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04283461,13026557,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04472585,13031367,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04472585,13031371,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04681053,12289038,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04678830,12289299,DRUG0164,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5),,,
NCT04678739,12289310,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04678739,12289310,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04678739,12289310,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04678739,12289311,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04673162,12290003,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04673149,12290004,DRUG0021,gls-5300,Vaccine,Middle East Respiratory Syndrome (MERS),Drug in Phase 1/2 Clinical Trial,,,,
NCT04672564,12290068,DRUG0071,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04669990,12290368,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04669990,12290368,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04669990,12290368,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04668469,12290555,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04668469,12290556,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04668209,12290604,DRUG0257,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2),CID: 24748573,Phase 1/2,Cholangiocarcinoma
NCT04667780,12290659,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04664010,12291123,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04664010,12291124,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04664010,12291125,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04661540,12291445,DRUG0079,cm4620,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 122507647,,
NCT04661527,12291447,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04530604,12307449,DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04530578,12307452,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04528927,12307662,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04528888,12307667,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04528888,12307668,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04527562,12307828,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04527211,12307876,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04524663,12308185,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04524663,12308185,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04524663,12308185,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04523571,12308317,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04523090,12308372,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04522986,12308380,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04273581,12341195,DRUG0068,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5426,Approved,Multiple myeloma
NCT04522466,12308441,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04521400,12308565,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04521400,12308566,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04521400,12308567,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04411433,12929374,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04388826,12929475,DRUG0306,veru-111,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 53379371,,
NCT04388683,12929476,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04372589,12929527,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04367883,12929546,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04363346,12929557,DRUG0053,ft516,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04351724,12929600,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351724,12929601,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04351724,12929607,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04351724,12929607,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04351724,12929607,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04346199,12929621,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK),CID: 71226662,Approved,Leukemia
NCT04341584,12929633,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04537949,12936856,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04476706,12937057,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04445272,12937171,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04380701,12937379,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04380701,12937380,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04380701,12937381,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04380701,12937382,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04369469,12937417,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04353180,12937458,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04353180,12937459,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04353180,12937460,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04315948,12937550,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04315948,12937550,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04315948,12937550,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04315948,12937551,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04315948,12937552,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04315948,12937553,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04466241,12942948,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04466241,12942949,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04409262,12943074,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04409262,12943074,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04409262,12943074,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04409262,12943075,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04663737,12946726,DRUG0257,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2),CID: 24748573,Phase 1/2,Cholangiocarcinoma
NCT04402970,12947333,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04382625,12947378,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04358549,12947438,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04330586,12947511,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04662086,12982479,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04662086,12982479,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04662086,12982479,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04662073,12982480,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04662073,12982480,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04662073,12982480,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04615429,12982815,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04492475,12983710,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04492475,12983712,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04492475,12983712,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04492475,12983712,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04486508,12983736,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04486508,12983737,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04486313,12983746,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04482712,12983761,DRUG0167,rapamycin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR),CID: 6436030,Approved,Lymphangioleiomyomatosis
NCT04482712,12983761,DRUG0167,rapamycin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR),CID: 6436030,Approved,Lymphangioleiomyomatosis
NCT04359680,12984349,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04359095,12984358,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04348383,12984397,DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04348071,12984399,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04659772,12291667,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04657458,12291937,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04652648,12292497,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04652115,12292568,DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04647695,12293078,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04647695,12293079,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647695,12293079,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647695,12293079,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647669,12293081,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647669,12293081,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647669,12293081,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04647669,12293082,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK),CID: 71226662,Approved,Leukemia
NCT04647669,12293083,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04646109,12293264,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04636671,12294402,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04635943,12294501,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04635241,12294582,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04634370,12294678,DRUG0061,natural killer cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04633772,12294754,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04632706,12294895,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04519385,12308808,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04516941,12309110,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04516915,12309113,DRUG0189,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH),CID: 9820008,,
NCT04516915,12309114,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04516811,12309128,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04510662,12309863,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04510493,12309882,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04505774,12310441,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04505774,12310442,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04501783,12310966,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04499677,12311243,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04499677,12311244,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04499313,12311285,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04498936,12311334,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04497948,12311471,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK),CID: 71226662,Approved,Leukemia
NCT04497519,12311517,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04494724,12311833,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04494399,12311873,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04494399,12311874,DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04494399,12311874,DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04494399,12311874,DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 37542,,
NCT04493359,12312004,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04492358,12312127,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04380961,13031564,DRUG0246,sirukumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 135626800,Phase 3,Rheumatoid arthritis
NCT04703608,13035482,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04428268,13036362,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04428268,13036362,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04428268,13036362,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04421027,13036393,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04412291,13036412,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04412291,13036413,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04716569,13040909,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04642638,13041074,DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04600141,13041200,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04600141,13041201,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04600141,13041202,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04583969,13041239,DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF),SID: 310264716,,
NCT04583969,13041241,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04583969,13041241,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04583969,13041241,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04583956,13041243,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04583956,13041243,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04583956,13041243,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04539262,13041330,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04539262,13041330,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04539262,13041330,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04510194,13041396,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1),CID: 4091,Approved,Type 2 diabetes
NCT04510038,13041398,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04464408,13041470,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04405739,13041556,DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04405570,13041558,DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04360096,13041644,DRUG0113,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 16132300,,
NCT04334148,13041668,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04727424,12283391,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04727424,12283392,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1),CID: 4091,Approved,Type 2 diabetes
NCT04727775,12283345,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04727775,12283346,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04727775,12283346,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04727775,12283346,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04724629,12283735,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04723563,12283862,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04720612,12284210,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04718480,12284461,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04718285,12284488,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04714515,12284969,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04714515,12284970,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04712279,12285267,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04711863,12285314,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04492501,12312110,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04492501,12312111,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04492501,12312111,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04492501,12312111,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04492501,12312112,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04490239,12312367,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04489446,12312456,DRUG0231,sildenafil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN phosphodiesterase type 5 (PDE5),CID: 135398744,Approved,Erectile dysfunction
NCT04488081,12312624,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04488081,12312624,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04488081,12312624,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04487990,12312646,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04487886,12312655,DRUG0160,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG),CID: 50905713,Approved,Follicular lymphoma
NCT04485429,12312946,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04485429,12312947,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04485130,12312980,DRUG0213,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04485130,12312980,DRUG0213,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04485130,12312980,DRUG0213,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO),,Approved,Alcohol dependence
NCT04483960,12313133,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04483960,12313133,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04483960,12313133,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04482686,12313290,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04479358,12313717,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04479358,12313718,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04477993,12313861,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04477083,12313964,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04476992,12313974,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04476992,12313975,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04476979,12313976,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04473053,12314415,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04473053,12314415,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04473053,12314415,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04470544,12314690,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04470544,12314690,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04470544,12314690,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04469491,12314822,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04467931,12315025,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04467931,12315026,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04467931,12315027,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04467047,12315138,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04466670,12315181,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04466670,12315182,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04466540,12315201,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04466280,12315226,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04466098,12315247,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04465695,12315308,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04463264,12315591,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04462757,12315642,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04461353,12315790,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04461340,12315792,DRUG0169,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR),CID: 5284616,Approved,Lymphangioleiomyomatosis
NCT04460547,12315895,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04460547,12315896,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04460547,12315897,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04460547,12315898,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04460183,12315949,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04459702,12316012,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04459702,12316013,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04459702,12316015,DRUG0178,lopinavir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV 3C-like protease (3CLpro),CID: 92727,Approved,Human immunodeficiency virus infection
NCT04459702,12316015,DRUG0178,lopinavir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV 3C-like proteinase (3CLpro),CID: 92727,Approved,Human immunodeficiency virus infection
NCT04459676,12316017,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04458948,12316103,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04458948,12316104,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04457609,12316254,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04457609,12316255,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04457609,12316256,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04456361,12316416,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04455958,12316449,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04455815,12316466,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04455815,12316466,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04455815,12316466,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04455243,12316537,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04629105,12295348,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04628143,12295454,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04628143,12295454,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04628143,12295454,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04627467,12295535,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04627467,12295535,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04627467,12295535,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04626089,12295731,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1),CID: 4091,Approved,Type 2 diabetes
NCT04625985,12295747,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1),CID: 4091,Approved,Type 2 diabetes
NCT04625738,12295786,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04625114,12295854,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04625114,12295854,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04625114,12295854,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04625114,12295856,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04625114,12295856,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04625114,12295856,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04622891,12296115,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04619680,12296517,DRUG0077,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135423438,Approved,Idiopathic pulmonary fibrosis
NCT04613271,12297275,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04613271,12297276,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04610541,12297580,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04610541,12297580,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04610541,12297580,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04608266,12297882,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04608266,12297882,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04608266,12297882,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04608214,12297886,DRUG0264,alisporivir,Protein/peptide drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN cyclophilin A (CYPA),CID: 11513676,Phase 3,Hepatitis C virus infection
NCT04608214,12297886,DRUG0264,alisporivir,Protein/peptide drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN cyclophilin A (CYPA),CID: 11513676,Phase 3,Hepatitis C virus infection
NCT04606563,12298097,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04605887,12298202,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04605588,12298236,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04605588,12298238,DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04605588,12298238,DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04605588,12298238,DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 37542,,
NCT04605588,12298240,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04604678,12298346,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1),CID: 4091,Approved,Type 2 diabetes
NCT04604678,12298347,DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04604327,12298386,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04603742,12298464,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04603729,12298467,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04603690,12298472,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04602507,12298608,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04601077,12298773,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04600999,12298783,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04600895,12298793,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04597775,12299122,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04596839,12299237,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04596839,12299237,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04596839,12299237,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04594343,12299541,DRUG0213,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04594343,12299541,DRUG0213,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04594343,12299541,DRUG0213,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO),,Approved,Alcohol dependence
NCT04590274,12300080,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04590274,12300082,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04588480,12300286,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04586153,12300605,DRUG0251,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 153241,Phase 2b,Hepatitis C virus infection
NCT04584580,12300823,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04582266,12301086,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04582266,12301086,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04582266,12301086,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04581954,12301116,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04577534,12301625,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04577378,12301641,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04577378,12301642,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04575064,12301933,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04575064,12301933,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04575064,12301933,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04575558,12301880,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04570501,12302474,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04570449,12302481,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04570397,12302493,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04570254,12302516,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04569383,12302620,DRUG0016,mva-sars-2,Vaccine,Middle East Respiratory Syndrome (MERS),Discontinue Drug in Phase 1 Clinical Trial,,,,
NCT04566276,12303016,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04565665,12303086,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04343248,12984419,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04340232,12984435,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04335084,12984479,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04668950,12992181,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04643678,12992292,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04511923,12992891,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04409483,12993170,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04381936,12993257,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04381936,12993259,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04381936,12993260,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04381936,12993262,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04381936,12993266,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04381936,12993267,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04381936,12993268,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04372602,12993303,DRUG0160,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG),CID: 50905713,Approved,Follicular lymphoma
NCT04368728,12993314,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04368728,12993315,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04349371,12993361,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04349371,12993361,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04349371,12993361,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04337918,12993389,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04337918,12993390,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04730206,13002397,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04730206,13002397,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04730206,13002397,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04713553,13002462,DRUG0056,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04680949,13002575,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04652765,13002659,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04652765,13002659,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04652765,13002659,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04431453,13003419,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04431453,13003419,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04431453,13003419,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04405076,13003471,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04391309,13003508,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04391309,13003508,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04391309,13003508,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04376814,12326149,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04376814,12326150,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04376814,12326151,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04376684,12326170,DRUG0229,otilimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF),SID: 381127828,Phase 3,Rheumatoid arthritis
NCT04366050,12327752,DRUG0241,ramipril,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme (ACE),CID: 5362129,Approved,Heart failure
NCT04375202,12326445,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04374942,12326481,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04374552,12326525,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04374461,12326547,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04374149,12326593,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04374071,12326602,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04374032,12326606,DRUG0119,metenkefalin + tridecactide,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT04374019,12326608,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04374019,12326609,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04374019,12326609,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04374019,12326609,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04373824,12326638,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04373044,12326763,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04373044,12326764,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04372628,12326834,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04372082,12326908,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04372082,12326909,DRUG0134,diltiazem + niclosamide,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04372017,12326915,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04371978,12326920,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4),CID: 10096344,Approved,Type 2 diabetes
NCT04371926,12326929,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04371822,12326937,DRUG0047,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 73755113,,
NCT04371822,12326938,DRUG0047,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 73755113,,
NCT04371822,12326939,DRUG0047,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 73755113,,
NCT04371822,12326940,DRUG0046,sulfonatoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 129653953,,
NCT04371640,12326965,DRUG0169,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR),CID: 5284616,Approved,Lymphangioleiomyomatosis
NCT04371601,12326971,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04371523,12326984,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04371406,12326995,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04371367,12327010,DRUG0162,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR),,,
NCT04371107,12327044,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04370834,12327087,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04370782,12327091,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04370782,12327092,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04370288,12327166,DRUG0050,"mcn (methylene blue, vitamin c, n-acetyl cysteine)",Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04370262,12327168,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04370015,12327190,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04369742,12327224,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04364022,12328061,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04369365,12327288,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04366323,12327710,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04368351,12327434,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04368351,12327435,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04367831,12327488,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04367831,12327489,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04367168,12327581,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04366739,12327643,DRUG0199,chlorpromazine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04366739,12327643,DRUG0199,chlorpromazine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04366739,12327643,DRUG0199,chlorpromazine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04366271,12327720,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04366232,12327727,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04366115,12327737,DRUG0060,avm0703,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04366089,12327745,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04366089,12327746,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04365985,12327761,DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04365985,12327762,DRUG0085,ketamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 3821,Approved,Anaesthesia
NCT04365725,12327796,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04365725,12327796,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04365725,12327796,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04365582,12327810,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04365582,12327811,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04365582,12327812,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04365517,12327820,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4),CID: 10096344,Approved,Type 2 diabetes
NCT04365231,12327865,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04365127,12327878,DRUG0045,progesterone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 5994,Approved,Amenorrhea
NCT04365101,12327882,DRUG0065,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04364984,12327911,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04364815,12327935,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04364009,12328064,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04363866,12328084,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04363853,12328086,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04363736,12328104,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04363450,12328134,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04363437,12328136,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04363203,12328169,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04363203,12328170,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04362332,12328268,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04362332,12328268,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04362332,12328268,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04362332,12328269,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04362189,12328287,DRUG0108,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04362137,12328294,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04362111,12328301,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04361942,12328324,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04361552,12328371,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04361461,12328380,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04361461,12328381,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04361422,12328384,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04361214,12328417,DRUG0188,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH),CID: 3899,Approved,Multiple sclerosis
NCT04361032,12328450,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04361032,12328451,DRUG0057,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 2973,Approved,Acute iron or aluminum toxicity
NCT04360980,12328457,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04360759,12328488,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04360551,12328511,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04360122,12328570,DRUG0136,levamisole + isoprinosine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04359953,12328593,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04359953,12328594,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04359953,12328595,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04359901,12328597,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04453839,12316711,DRUG0113,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 16132300,,
NCT04452474,12316890,DRUG0248,olokizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160677293,Phase 3,Rheumatoid Arthritis
NCT04451291,12317045,DRUG0304,decidual stromal cells (dsc),Protein/peptide drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,HUMAN dibasic-processing enzyme (Furin),CID: 9962075,,
NCT04449380,12317272,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04448119,12317403,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04447833,12317435,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04447781,12317443,DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04447534,12317478,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04447534,12317478,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04447534,12317478,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04447235,12317518,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04447235,12317519,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04446104,12317666,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04446104,12317667,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04445467,12317779,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04445454,12317780,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04445311,12317794,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04444986,12317829,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04444986,12317830,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04444674,12317856,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04444271,12317896,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04443881,12317950,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04443868,12317951,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04443270,12318028,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04443270,12318028,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04443270,12318028,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04441424,12318250,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04441398,12318252,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04438980,12318540,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04438850,12318550,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04438837,12318552,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04437693,12318676,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04435808,12318928,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04435717,12318936,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04435717,12318937,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04435587,12318957,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04435314,12318984,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04435015,12319014,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04435015,12319014,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04435015,12319014,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04434248,12319091,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04434144,12319102,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04431466,12319415,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04429867,12319617,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04429763,12319629,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04425707,12320134,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04425460,12320164,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04425382,12320176,DRUG0221,darunavir + cobicistat,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04425382,12320177,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04423861,12320368,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04423042,12320473,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04421664,12320611,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04420247,12320782,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320782,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320782,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320783,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04418128,12321028,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04418128,12321028,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04418128,12321028,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04416139,12321257,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04415151,12321377,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04414241,12321483,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04412772,12321633,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04412252,12321703,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04410562,12321928,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04410354,12321953,DRUG0251,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 153241,Phase 2b,Hepatitis C virus infection
NCT04410354,12321955,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04410354,12321955,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04410354,12321955,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04409834,12322027,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04409834,12322030,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04408326,12322205,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04407507,12322287,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04407000,12322348,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04407000,12322349,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04406389,12322414,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04406246,12322434,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04405921,12322467,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04405921,12322468,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04403685,12322745,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04403555,12322756,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04403243,12322793,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04403243,12322794,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04403100,12322815,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04403100,12322816,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04403100,12322817,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04402203,12322916,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04401579,12322987,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04401579,12322987,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04401579,12322987,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04401579,12322988,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04400838,12323079,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400838,12323081,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400838,12323083,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400838,12323084,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400838,12323086,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400838,12323087,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04400032,12323178,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04400019,12323179,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04399889,12323198,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04399798,12323209,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04399746,12323215,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04399746,12323216,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04398290,12323388,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04398004,12323417,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04397796,12323428,DRUG0064,bm-mscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04397510,12323459,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04397328,12323489,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04395768,12323674,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04395768,12323675,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04394442,12323831,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04394416,12323832,DRUG0125,imatinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394416,12323832,DRUG0125,imatinib,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl),CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394416,12323832,DRUG0125,imatinib,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl),CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394377,12323836,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04394182,12323856,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04394182,12323857,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04394182,12323858,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04394182,12323860,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04394182,12323862,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04394117,12323868,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04393805,12323900,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04392713,12324025,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04392219,12324084,DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04392128,12324094,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04392128,12324095,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04391127,12324203,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04391127,12324204,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04390594,12324272,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04390594,12324272,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04390594,12324272,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04390464,12324282,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04390464,12324283,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04390152,12324329,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04390061,12324342,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04390061,12324343,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04390022,12324348,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04389580,12324390,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04389580,12324391,DRUG0205,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO),CID: 5282379,,
NCT04389359,12324411,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04389320,12324415,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04388709,12324486,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04387786,12324581,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04387760,12324583,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04387760,12324584,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04386876,12324720,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04386876,12324721,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04386239,12324808,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04386070,12324829,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04386070,12324830,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04385264,12324947,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT03183570,12479571,DRUG0222,asc09 + ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT03331445,12460438,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT03852537,12393571,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT03871491,12391106,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT03891420,12388642,DRUG0232,galidesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 69211190,,
NCT03891420,12388642,DRUG0232,galidesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 69211190,,
NCT03891420,12388642,DRUG0232,galidesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 69211190,,
NCT03808922,13042515,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT03808922,13042517,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT03808922,13042518,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04708327,12285763,DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04699097,12286855,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04694612,12287407,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04694612,12287409,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04694612,12287409,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04694612,12287409,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04693026,12287606,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04693026,12287606,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04693026,12287606,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04693026,12287607,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04693026,12287608,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04690920,12287836,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04306705,12336390,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04306393,12336426,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04305106,12336611,DRUG0190,bevacizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN vascular endothelial growth factor (VEGF),,Approved,Metastatic colorectal cancer
NCT04305457,12336574,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04304313,12336730,DRUG0231,sildenafil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN phosphodiesterase type 5 (PDE5),CID: 135398744,Approved,Erectile dysfunction
NCT04303507,12336852,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04302766,12336977,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04302766,12336977,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04302766,12336977,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04302519,12337003,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04299724,12337443,DRUG0039,pathogen-specific aapc,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04298060,12337659,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04295551,12338050,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04293887,12338299,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04292899,12338431,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04292899,12338431,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04292899,12338431,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04292730,12338472,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04292730,12338472,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04292730,12338472,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04290871,12338770,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04290858,12338771,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04288713,12339078,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04287686,12339216,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04286503,12339374,DRUG0071,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04286503,12339375,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04280705,12340201,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04280705,12340201,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04280705,12340201,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04280588,12340224,DRUG0070,fingolimod,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 107970,Approved,Multiple sclerosis
NCT04276688,12340754,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04276688,12340755,DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04276688,12340755,DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04276688,12340755,DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 37542,,
NCT04276688,12340756,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04275414,12340953,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04275388,12340955,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04275245,12340981,DRUG0251,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),CID: 153241,Phase 2b,Hepatitis C virus infection
NCT04273763,12341170,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04273529,12341204,DRUG0068,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5426,Approved,Multiple myeloma
NCT04273321,12341223,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04268537,12341953,DRUG0089,thymosin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 44286042,,
NCT04263402,12342796,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04263402,12342797,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04261517,12343072,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04261907,12343015,DRUG0216,asc09 + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04261907,12343016,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04261270,12343111,DRUG0222,asc09 + ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04261270,12343112,DRUG0130,ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04261270,12343113,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04260594,12343226,DRUG0067,arbidol,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 131410,Phase 4,Influenza virus infection
NCT04257656,12343641,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04257656,12343641,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04257656,12343641,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04255017,12344072,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04255017,12344073,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04252664,12344414,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04252664,12344414,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04252664,12344414,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04252274,12344464,DRUG0221,darunavir + cobicistat,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04251871,12344511,DRUG0215,lopinavir + ritonavir + interferon apha + traditional chinese medicines granules,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04251871,12344512,DRUG0215,lopinavir + ritonavir + interferon apha + traditional chinese medicines granules,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro),,,
NCT04244591,12345519,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04148430,12357438,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04561219,12303608,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04561063,12303628,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04560231,12303731,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04560231,12303731,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04560231,12303731,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04560205,12303734,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04559113,12303857,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04558463,12303932,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04558463,12303933,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04554979,12304379,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04552483,12304690,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04552379,12304704,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04552366,12304705,DRUG0066,ad5-ncov,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04545541,12305575,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04545008,12305643,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04542694,12305927,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04542408,12305965,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04542213,12305987,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4),CID: 10096344,Approved,Type 2 diabetes
NCT04541680,12306055,DRUG0077,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135423438,Approved,Idiopathic pulmonary fibrosis
NCT04539873,12306304,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04537351,12306616,DRUG0065,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04536350,12306754,DRUG0113,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 16132300,,
NCT04536051,12306791,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04536051,12306793,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04535856,12306814,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04534725,12306937,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04534725,12306938,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04534725,12306939,DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF),SID: 310264716,,
NCT04532931,12307153,DRUG0012,amodiaquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,,CID: 2165,Withdrawn from market,Malaria
NCT04532931,12307153,DRUG0012,amodiaquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,,CID: 2165,Withdrawn from market,Malaria
NCT04532372,12307224,DRUG0188,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH),CID: 3899,Approved,Multiple sclerosis
NCT04384458,12325072,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04384458,12325073,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04384380,12325079,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04383717,12325178,DRUG0136,levamisole + isoprinosine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04383717,12325179,DRUG0196,azithromycin + hydroxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),,,
NCT04382066,12325401,DRUG0048,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 9812534,,
NCT04382053,12325402,DRUG0094,dfv890,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04383002,12325279,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04382846,12325297,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04381364,12325518,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04382547,12325340,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04382066,12325399,DRUG0048,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 9812534,,
NCT04382066,12325400,DRUG0048,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,CID: 9812534,,
NCT04382040,12325408,DRUG0088,artemic,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 11629819,,
NCT04381988,12325415,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04381962,12325421,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04381884,12325441,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04381052,12325551,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04729491,12325680,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04729491,12325681,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04380818,12325586,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04380818,12325587,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04380818,12325588,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04380818,12325589,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04380818,12325591,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04380688,12325609,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK),CID: 71226662,Approved,Leukemia
NCT04380519,12325643,DRUG0248,olokizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160677293,Phase 3,Rheumatoid Arthritis
NCT04380402,12325656,DRUG0158,atorvastatin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN MYD88-NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway),CID: 60823,Approved,Hyperlipidemia
NCT04380376,12325660,DRUG0087,melphalan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 460612,Approved,Ovarian neoplasms
NCT04379518,12325793,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04379518,12325794,DRUG0155,rintatolimod,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN toll-like receptor 3 (TLR3),CID: 135537060,Phase 3,Chronic Fatigue Syndrome
NCT04379492,12325797,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04379479,12325799,DRUG0110,dialyzable leukocyte cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04379310,12325827,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04379271,12325830,DRUG0189,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH),CID: 9820008,,
NCT04728880,12326101,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04728880,12326101,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04728880,12326101,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04377750,12326045,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04377711,12326047,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04377659,12326055,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04377646,12326056,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04377620,12326063,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04377503,12326077,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04377503,12326078,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04377308,12326095,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04359667,12328631,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04359654,12328632,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04359615,12328635,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04359615,12328636,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04359537,12328642,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04359316,12328678,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04359316,12328679,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04359290,12328683,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04359212,12328695,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04358588,12328794,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04358068,12328877,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04358068,12328878,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04357860,12328910,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04357860,12328911,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04357535,12328959,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04356937,12329042,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04356690,12329086,DRUG0083,etoposide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 36462,Approved,Testicular neoplasms
NCT04356495,12329111,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04356495,12329112,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04356495,12329113,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04355936,12329203,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 65999,Approved,Hypertension
NCT04355793,12329232,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04355728,12329237,DRUG0107,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Epidermolysis Bullosa
NCT04355676,12329243,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04355494,12329273,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04355429,12329281,DRUG0242,captopril,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN angiotensin-converting enzyme (ACE),CID: 44093,Approved,Hypertension
NCT04355364,12329288,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04355247,12329308,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04355143,12329318,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04355052,12329333,DRUG0131,hydroxychloroquine + camostat mesylate,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04355052,12329334,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04354870,12329362,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04354805,12329368,DRUG0199,chlorpromazine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04354805,12329368,DRUG0199,chlorpromazine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04354805,12329368,DRUG0199,chlorpromazine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN clathrin-mediated endocytosis (RME),CID: 2726,Withdrawn from market,Schizophrenia
NCT04354714,12329378,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04354441,12329417,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04354428,12329422,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04354428,12329423,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04354428,12329425,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04354389,12329428,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04354389,12329430,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04354259,12329446,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04353596,12329541,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04353336,12329581,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04353284,12329589,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04353284,12329589,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04353284,12329589,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04353271,12329593,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04352933,12329644,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04352933,12329645,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04352465,12329709,DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04352465,12329710,DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04352465,12329711,DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04352400,12329717,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04352400,12329717,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04352400,12329717,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04351919,12329804,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351919,12329805,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04351516,12329867,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351763,12329825,DRUG0186,amiodarone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2),CID: 2157,Approved,Ventricular tachycardia
NCT04351763,12329826,DRUG0185,verapamil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2),CID: 2520,Approved,High blood pressure
NCT04351620,12329852,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351347,12329898,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04351295,12329908,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04351191,12329927,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351191,12329928,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04351191,12329929,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04351191,12329929,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04351191,12329929,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04351152,12329935,DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF),SID: 310264716,,
NCT04350684,12330016,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350684,12330017,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04350684,12330018,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04350671,12330020,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350671,12330021,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04350671,12330022,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04350450,12330060,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04350320,12330083,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04350281,12330090,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350281,12330091,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04349631,12330183,DRUG0108,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04349592,12330192,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04349592,12330193,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04480138,12330336,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04349410,12330224,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04349410,12330226,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04349410,12330229,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04349410,12330229,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04349410,12330229,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04349410,12330230,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04349410,12330231,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04349410,12330232,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04349410,12330233,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04349241,12330254,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04349228,12330256,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04349098,12330272,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04348695,12330322,DRUG0104,ruxolitinib plus simvastatin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04348500,12330348,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04348474,12330350,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04348474,12330351,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04348461,12330352,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04348435,12330354,DRUG0108,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04348409,12330359,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04347980,12330416,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04347915,12330426,DRUG0080,clevudine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 73115,Phase 4,Hepatitis B
NCT04347889,12330429,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04347512,12330470,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04347512,12330471,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04347239,12330511,DRUG0164,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5),,,
NCT04347226,12330512,DRUG0159,bms-986253,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 8 (IL8),SID: 385157372,,
NCT04347031,12330536,DRUG0013,mefloquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,,CID: 40692,Approved,Malaria
NCT04347031,12330536,DRUG0013,mefloquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,,CID: 40692,Approved,Malaria
NCT04347031,12330536,DRUG0013,mefloquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 40692,Approved,Malaria
NCT04347031,12330537,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04346797,12330580,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04346667,12330606,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04346667,12330607,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04346667,12330608,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04346667,12330608,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04346667,12330608,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04346628,12330613,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04346355,12330655,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04346329,12330658,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04345861,12330719,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04345692,12330755,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04345653,12330759,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04345445,12330786,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04345445,12330787,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04345419,12330790,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04345419,12330791,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04345419,12330791,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04345419,12330791,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04345406,12330792,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04345276,12330815,DRUG0099,danoprevir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04344782,12330879,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04344756,12330881,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04344600,12330903,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343729,12331038,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04344548,12330908,DRUG0063,allogeneic nk transfer,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04344457,12330925,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04344457,12330926,DRUG0058,indomethacin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 3715,Approved,Rheumatoid arthritis
NCT04344444,12330930,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04344444,12330931,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04344379,12330940,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04344379,12330941,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04343989,12330991,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04343989,12330992,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 160671637,,
NCT04343976,12330994,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343768,12331030,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04343768,12331031,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04343768,12331032,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343768,12331033,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343651,12331047,DRUG0164,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5),,,
NCT04343001,12331125,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04342897,12331142,DRUG0161,ly3127804,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiopoietin-2 (ANG-2),,,
NCT04342663,12331166,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04342650,12331168,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04342650,12331168,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04342650,12331168,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04342221,12331221,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04342169,12331225,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04342156,12331227,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341935,12331253,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4),CID: 10096344,Approved,Type 2 diabetes
NCT04341870,12331261,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04341870,12331262,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341870,12331263,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04372186,12331401,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04341727,12331287,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341727,12331288,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341727,12331289,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04341727,12331289,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04341727,12331289,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04341675,12331295,DRUG0169,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR),CID: 5284616,Approved,Lymphangioleiomyomatosis
NCT04341493,12331323,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04341493,12331324,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341441,12331334,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341441,12331335,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341207,12331368,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04341207,12331369,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341116,12331390,DRUG0228,tj003234,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF),,,
NCT04341038,12331399,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04340557,12331465,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04340544,12331466,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04340349,12331498,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04338958,12331693,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04339816,12331574,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04339816,12331575,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04339712,12331601,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04339712,12331602,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04339426,12331627,DRUG0100,atovaquone + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04338906,12331703,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04338906,12331703,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04338906,12331703,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04338906,12331705,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04338802,12331721,DRUG0077,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135423438,Approved,Idiopathic pulmonary fibrosis
NCT04338698,12331740,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04338698,12331741,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04338698,12331742,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04333472,12331772,DRUG0075,piclidenoson,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 123683,Phase 3,Keratoconjunctivitis Sicca
NCT04337359,12331936,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04336904,12331982,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04336748,12332002,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04336410,12332056,DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04336254,12332078,DRUG0062,allogeneic human dental pulp stem cells (bsh btc & utooth btc),Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04335552,12332172,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04335552,12332173,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04335305,12332204,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04335136,12332224,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04335123,12332227,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1),CID: 3961,Approved,Hypertension
NCT04335071,12332234,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04334980,12332253,DRUG0041,bactrl-spike,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04334967,12332254,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04334928,12332264,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04334512,12332329,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04334512,12332330,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04334460,12332341,DRUG0156,bld-2660,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN calpain-2/calpain small subunit 1 dimer (CAPN2/CAPNS1),,,
NCT04334382,12332351,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04334382,12332352,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04333914,12332439,DRUG0162,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR),,,
NCT04333914,12332440,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04333654,12332467,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04333628,12332469,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04333628,12332469,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04333628,12332469,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04333589,12332475,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04333550,12332488,DRUG0057,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 2973,Approved,Acute iron or aluminum toxicity
NCT04333420,12332505,DRUG0166,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2),,,
NCT04333225,12332536,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04332991,12332570,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04332666,12332619,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04332107,12332695,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04332094,12332697,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04332094,12332698,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04332094,12332699,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04332042,12332708,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04331899,12332727,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04331808,12332732,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04331795,12332733,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04331795,12332734,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04331665,12332761,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2),CID: 25126798,Approved,Myelofibrosis
NCT04331470,12332784,DRUG0115,levamisole pill + budesonide+formoterol inhaler,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT04331470,12332785,DRUG0116,lopinavir + ritonavir + hydoxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT04330690,12332887,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04330690,12332888,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04330690,12332888,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04330690,12332888,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04330638,12332897,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04330638,12332898,DRUG0249,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 124490409,Approved,Idiopathic multicentric Castleman disease
NCT04330638,12332899,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04330495,12332914,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04330300,12332947,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04330300,12332948,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04329923,12332997,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329923,12332998,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329923,12332999,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329832,12333011,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329832,12333012,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04329650,12333030,DRUG0249,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6),SID: 124490409,Approved,Idiopathic multicentric Castleman disease
NCT04329650,12333031,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04329611,12333035,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329572,12333043,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04329572,12333044,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04328961,12333119,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04328493,12333184,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04328493,12333184,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04328493,12333184,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04328480,12333185,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04328467,12333188,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04328285,12333207,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04328285,12333209,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04328272,12333211,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04328272,12333212,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04327388,12333337,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04326790,12333420,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04326426,12333477,DRUG0122,tradipitant,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 9916461,,
NCT04325893,12333550,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04324606,12333713,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04324606,12333715,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04324606,12333716,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04324606,12333719,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04324489,12333731,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04324463,12333735,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04324463,12333736,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04324073,12333813,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04324021,12333818,DRUG0183,emapalumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interferon gamma (IFNG),SID: 318164814,Approved,Primary haemophagocytic lymphohistiocytosis
NCT04324021,12333819,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT04323761,12333862,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04323761,12333862,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04323761,12333862,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04323631,12333878,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04323592,12333882,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04323527,12333895,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04323527,12333895,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04323527,12333895,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 2719,Withdrawn from market,Malaria
NCT04322786,12334008,DRUG0114,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 123805,,
NCT04322682,12334022,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04322565,12334040,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04322123,12334111,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04322123,12334112,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04321616,12334202,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04321616,12334203,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04321616,12334203,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04321616,12334203,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 121304016,,
NCT04321278,12334254,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04321278,12334255,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04321174,12334266,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04321096,12334280,DRUG0171,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04321096,12334280,DRUG0171,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04321096,12334280,DRUG0171,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2),CID: 5284360,,
NCT04320615,12334329,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04320277,12334380,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK),CID: 44205240,Approved,Rheumatoid arthritis
NCT04320238,12334384,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04320238,12334385,DRUG0089,thymosin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 44286042,,
NCT04318444,12334655,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04318015,12334701,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04317092,12334826,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04316377,12334931,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04315896,12335018,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04315480,12335086,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04315298,12335109,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT04313023,12335437,DRUG0157,pul-042,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN toll-like receptor 9 (TLR9),,,
NCT04312997,12335442,DRUG0157,pul-042,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN toll-like receptor 9 (TLR9),,,
NCT04312243,12335529,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04310228,12335856,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04310228,12335857,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
NCT04308668,12336098,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT04307693,12336251,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT04307693,12336252,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT02735707,12538969,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1),CID: 139595263,Approved,Rheumatoid arthritis
NCT02735707,12538963,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT02735707,12538966,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR),CID: 3652,Approved,Malaria
NCT02735707,12538967,DRUG0116,lopinavir + ritonavir + hydoxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT02735707,12538968,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT02735707,12538965,DRUG0220,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro),CID: 11979606,Approved,Human immunodeficiency virus infection
NCT02735707,12538972,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Rheumatoid arthritis
NCT02735707,12538964,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT02735707,12538971,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R),,Approved,Giant cell arteritis
